Copy of Sublicenses and Sublicense Royalty Reports Sample Clauses

Copy of Sublicenses and Sublicense Royalty Reports. Licensee shall submit to University a copy of each Sublicense, any subsequent amendments and all copies of Sublicensee’s royalty reports. PAYMENT, RECORDS, AND AUDIT Licensee’s Payment Obligation The Licensee shall pay all amounts under Section 7 and 10 of the Business Terms by the dates indicated therein. Licensee shall pay such amounts by wire transfer, check (payable to the “Regents of the University of Minnesota” and sent to: Regents of the University of Minnesota, NW 5960, XX Xxx 0000, Xxxxxxxxxxx, XX 00000-0000; reference agreement number on check), or any other method of payment specified by University. Licensee Responsible for Non-U.S. Taxes Licensee shall pay all non-U.S. taxes related to payments made to University under this Agreement. Interest on Late Payments All amounts due under this Agreement will bear compound interest at 12% per annum on the entire unpaid balance computed from the due date until the amount is paid. Royalty Payments/Sales Reports Within sixty (60) days after the last day of the fourth calendar quarter beginning in the calendar year in which Licensee, Sublicensee or Affiliate first sells a Licensed Product, Licensee shall provide to the University a written report (even if there are no sales) and earned royalty payment under Section 10.4 of the Business Terms in a form acceptable to the University. No Refund All amounts paid to the University (and, if applicable, all equity transferred to University under Section 10.1 of the Business Terms) are non-refundable.
AutoNDA by SimpleDocs
Copy of Sublicenses and Sublicense Royalty Reports. Licensee shall submit to University within [***] of the effective date of a Sublicense a copy of such Sublicense in accordance with the terms of Section 3.1 of the General Terms, any subsequent amendments of the Sublicense and all copies of Sublicensee’s royalty reports. OTC Agreement Number: [***] OTC Case Number: [***]
Copy of Sublicenses and Sublicense Royalty Reports. Licensee shall submit to University a copy of each Sublicense, any subsequent amendments and all copies of Sublicensee’s royalty reports. Sharing of Sublicensing Consideration. Licensee shall pay to University a portion of Sublicense Consideration received from Sublicensee as provided in Section 10.6 of the Business Terms. PAYMENT, RECORDS, AND AUDIT Licensee’s Payment Obligation The Licensee shall pay all amounts under Section 7 and 10 of the Business Terms by the dates indicated therein. Licensee shall pay such amounts by wire transfer, check (payable to the “Regents of the University of Minnesota” and sent to: Regents of the University of Minnesota, NW 5960, XX Xxx 0000, Xxxxxxxxxxx, XX 00000-0000; reference agreement number on check), or any other method of payment specified by University. Licensee Responsible for Non-U.S. Taxes Licensee shall pay all non-U.S. taxes related to payments made to University under this Agreement. Interest on Late Payments All amounts due under this Agreement will bear compound interest at 12% per annum on the entire unpaid balance computed from the due date until the amount is paid. Security for Reimbursement of Patent-Related Expenses The University reserves the right to require that Licensee provide and maintain a reasonable advance deposit with the University or some other form of security to ensure payment of Patent-Related Expenses.
Copy of Sublicenses and Sublicense Royalty Reports. Licensee shall submit to University a copy of each Sublicense, any subsequent amendments and all copies of Sublicensee’s royalty reports.

Related to Copy of Sublicenses and Sublicense Royalty Reports

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Royalty Reports After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY quarterly royalty reports on or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar quarter and shall show:

  • Assignment and Sublicensing This Licence is personal to the Licensee. The Licensee must not dispose of, deal with, transfer, novate or assign its rights as Licensee under this Licence without obtaining the School Council’s prior written consent, which consent is at the absolute discretion of the School Council, and if granted, may be granted subject to such conditions as the School Council see fit to impose.

  • PROGRESS AND ROYALTY REPORTS 8.1 For the period beginning [date] LICENSEE will submit to REGENTS a semi-annual progress report covering LICENSEE's activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.

  • Sublicense Revenue In the event Licensee or an Affiliate of Licensee sublicenses under Section 2.2, Licensee shall pay CareFusion **THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION.** of any Sublicense Revenues resulting from sublicense agreements executed by Licensee.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Royalty Report The term “Royalty Report” shall have the meaning ascribed to such term as provided in Section 5.4.

  • Sublicense Agreements Sublicenses shall only be granted pursuant to written agreements, which shall be in compliance and not inconsistent with and shall be subject and subordinate to the terms and conditions of this Agreement (each, a "Sublicense Agreement"). Each such sublicense agreement shall contain, among other things, provisions to the following effect:

  • Sublicense (a) The license granted in Paragraph 2.1 includes the right of LICENSEE to grant Sublicenses to third parties during the Term but only for as long as the license to Patent Rights is exclusive.

  • Sublicensing Rights Novartis and its Affiliates may grant sublicenses of the license granted in Section 5.3.1(a), Section 5.3.2, and Section 5.3.3, and Intellia and its Affiliates may grant sublicenses of the license granted in Section 5.3.1(b), provided that (a) such sublicense (i) is in writing, (ii) is subject and subordinate to, and consistent with, the terms and conditions of this Agreement, and (iii) requires the applicable sublicensee to comply with all applicable terms of this Agreement [***]; (b) with respect to Novartis or any of its Affiliates as the sublicensing Party to the extent required by the Key License Agreements as in effect on the Effective Date or the agreements for any Included Intellia New In-Licensed Intellectual Property, Novartis promptly notifies Intellia of the grant of each sublicense and provides Intellia a copy of the final executed sublicense agreement, redacted for information not pertinent to this Agreement to the extent that such redactions do not reasonably impair Intellia’s ability to ensure compliance with this Agreement, the Key License Agreements or agreements for any Included Intellia New In-Licensed Intellectual Property, as applicable, (c) Novartis or Intellia, as applicable, shall be responsible for the failure by its sublicensees to comply with, and Novartis or Intellia, as applicable, guarantees the compliance by each of its sublicensees with, all relevant restrictions, limitations and obligations in this Agreement, and [***]. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Time is Money Join Law Insider Premium to draft better contracts faster.